Product Description
Mechanisms of Action: nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: FORUM
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Schizophrenia|Cognitive Dysfunction|Alzheimer Disease
Phase 2: Alzheimer Disease|Schizophrenia|Tobacco Use Disorder|Smoking Cessation
Phase 1: Kidney Diseases|Other|Healthy Volunteers|Affective Disorders, Psychotic|Alzheimer Disease|Psychotic Disorders|Schizophrenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01984736 |
EVP-6124-020 | P1 |
Completed |
Other |
2014-12-01 |
2019-03-20 |
Treatments |
|
NCT01984723 |
EVP-6124-019 | P1 |
Completed |
Kidney Diseases |
2014-02-01 |
2019-03-20 |
Treatments |
|
NCT01487135 |
TQT | P1 |
Completed |
Healthy Volunteers |
2013-09-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00766363 |
EVP-6124-007 | P1 |
Completed |
Alzheimer Disease |
2009-03-01 |
2019-03-18 |
Treatments |
|
NCT01556763 |
EVP-6124-005 | P1 |
Completed |
Schizophrenia|Psychotic Disorders|Affective Disorders, Psychotic |
2008-08-01 |
2019-03-19 |
Treatments |
|
NCT02246075 |
EVP-6124-027 | P2 |
Withdrawn |
Alzheimer Disease |
2016-10-01 |
2019-03-20 |
Treatments |
|
NCT01480232 |
EVP-6124-014 | P2 |
Terminated |
Smoking Cessation|Tobacco Use Disorder |
2015-09-01 |
2019-03-19 |
Treatments |
|
NCT01764243 |
P211-03 | P2 |
Completed |
Alzheimer Disease |
2015-06-01 |
2023-04-08 |
Primary Endpoints|Treatments |
|
NCT01073228 |
EVP-6124-010 | P2 |
Completed |
Alzheimer Disease |
2011-11-01 |
2019-03-19 |
Treatments |
|
NCT00968851 |
EVP-6124-009 | P2 |
Completed |
Schizophrenia |
2011-01-01 |
2019-03-19 |
Treatments |
|
NCT02004392 |
EVP-6124-026 | P3 |
Terminated |
Alzheimer Disease |
2017-08-01 |
2019-03-20 |
Treatments |
|
NCT01969123 |
EVP-6124-024 | P3 |
Terminated |
Alzheimer Disease |
2017-01-01 |
2019-03-20 |
||
NCT01969136 |
EVP-6124-025 | P3 |
Terminated |
Alzheimer Disease |
2017-01-01 |
2019-03-20 |
Treatments |
|
2012-003228-19 |
2012-003228-19 | P3 |
Terminated |
Schizophrenia |
2016-02-05 |
2025-06-29 |
Treatments |
|
NCT01716975 |
EVP-6124-016 | P3 |
Completed |
Cognitive Dysfunction|Schizophrenia |
2016-02-01 |
2019-03-19 |
Treatments |
|
2012-003208-10 |
2012-003208-10 | P3 |
Completed |
Schizophrenia |
2016-01-08 |
2022-03-13 |
Treatments |
|
2012-003209-92 |
2012-003209-92 | P3 |
Completed |
Schizophrenia |
2015-12-16 |
2022-03-13 |
Treatments |
|
NCT01714661 |
EVP-6124-015 | P3 |
Completed |
Schizophrenia|Cognitive Dysfunction |
2015-12-01 |
2019-03-19 |
Treatments |
|
2013-002618-10 |
2013-002618-10 | P3 |
Terminated |
Alzheimer Disease |
2015-11-20 |
2022-03-13 |
Treatments |
|
2013-002654-75 |
2013-002654-75 | P3 |
Terminated |
Alzheimer Disease |
2015-11-20 |
2025-07-09 |
Treatments |
|
2013-002653-30 |
2013-002653-30 | P3 |
Terminated |
Alzheimer Disease |
2015-11-11 |
2025-07-06 |
Treatments |
|
NCT01714713 |
EVP-6124-017 | P3 |
Completed |
Schizophrenia|Cognitive Dysfunction |
2015-10-01 |
2019-03-19 |
Treatments |
|
NCT02327182 |
P211-05 | P3 |
Terminated |
Alzheimer Disease |
2015-09-01 |
2025-08-27 |
Primary Endpoints|Treatments |